J.P. Morgan analyst Anupam Rama maintained a Hold rating on Chemocentryx Inc. on Monday, setting a price target of $40, which is approximately 2.88% above the present share price of $38.88.
Rama expects Chemocentryx Inc. to post earnings per share (EPS) of -$0.32 for the fourth quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in ChemoCentryx (NASDAQ:CCXI), with an average price target of $66.6.
The analysts price targets range from a high of $110 to a low of $30.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $17.69 million and a net profit of -$21.8 million. The company's market cap is $2.72 billion.
According to TipRanks.com, J.P. Morgan analyst Anupam Rama is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.6% and a 44.24% success rate.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.